Grifols and Shanghai RAAS alliance approved by China and USA
Spanish drugmaker Grifols (GRF: MC), a leader in plasma medicines, transfusion diagnosis and pharmaceutical specialties for hospital use, together with Shanghai RAAS (002252.SZ), a leader in China’s plasma derivatives sector, have earned approval from the Chinese and US regulatory authorities for their strategic alliance in China, including approval from the Committee on Foreign Investment in the USA (CFIUS) and the Chinese Securities Regulatory Commission (CRSC).
The operation is expected to finalize before the end of 20190.
Under the terms of the transaction, Shanghai RAAS will also become the exclusive distributor of Grifols’ plasma-derived products and diagnostic solutions in China.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze